^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IO102

    i
    Other names: IO102, IDOlong, IO 102, 21-mer IDO-derived peptide vaccine
    Associations

    News

    Trials
    Company:
    IO Biotech
    Drug class:
    IDO inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    KIEO: Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN). (clinicaltrials.gov)
    P2, N=15, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • IO102
    4years
    [VIRTUAL] Clinical efficacy and immunity of combination therapy with nivolumab and IDO/PD-L1 peptide vaccine in patients with metastatic melanoma: A phase I/II trial (ESMO 2020)
    Background The IDO/PD-L1 (IO102/IO103)1 peptide vaccine is a first-in-class immunomodulatory vaccine containing single IDO- and PD-L1-derived long peptide sequences designed to engage and activate IDO and PD-L1 specific T-cells mediating immune switch. Funding: Has not received any funding. Clinical trial identification: NCT03047928.
    Clinical • P1/2 data • Late-breaking abstract • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab) • IO102 • IO103